DEC 23, 2018 11:22 PM PST

Buruli ulcer: promising drug for a forgotten disease

WRITTEN BY: Nouran Amin

One of the most forgotten and neglected diseases is Buruli ulcer, a debilitating and stigmatized condition affecting primarily children in West and Central Africa. Buruli ulcer is caused by the bacterium Mycobacterium ulcerans and results in devastating skin lesions leading to permanent disfigurement and long-term disabilities.

Treatment for the disease considers surgical removal of skin lesions as well as antibiotics involving the combination of oral rifampicin and injected streptomycin. However, these treatments come with many limitations. For one, surgery is often not an accessible option especially in in low-income areas. Furtherer, administration of antibiotics requires daily visits to a health center and antibiotic use is often plagued with great side-effects resulting such as hearing loss in over 20% of treated patients. These challenges are pushing researchers to seek safer, accessible, and effective treatment options.

Now, in a study published in Nature Communications, researchers have developed a promising compound against Buruli ulcer. The compound, referred to as Q203 (an imidazopyridine amide), was concluded to be highly effective against Buruli ulcer during in vitro and in vivo studies.

"We were very surprised when we saw this high activity. We had previously screened hundreds of compounds that were originally intended for TB drug development and none of the others showed promising activity against Mycobacterium ulcerans," said Gerd Pluschke, Head of the Molecular Immunology Unit at Swiss TPH. "Q203, however, is even more effective against Buruli ulcer than the current most active antibiotic rifampicin. Such a new and exquisitely effective drug combined with a second antibiotic may result in a considerably shorter oral treatment regimen with fewer adverse side effects."

A promising new drug candidate may improve treatment options of Buruli ulcer patients.

Credit: Hubert Vuagnat via Swiss Tropical and Public Health Institute

What makes Q203 very advantageous for treatment is it has already been tested in a phase I clinical trial for Tuberculous. "That means that as soon as funding can be secured, we will directly test the new compound in Buruli ulcer patients in a phase II trial," says Pluschke.

Source: Swiss Tropical and Public Health Institute

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Common Anticonvulsant Drug May Counteract Inflammation
Sepsis is a serious medical condition that results from inflammation in the body and can cause fatal multi-organ dysfunction. The inflammation is usually t...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Understanding The Anti-Malarial Drug Primaquine (PQ)
Scientists at the Liverpool School of Tropical Medicine (LSTM) have advanced their experiments to understand the mode of action for the anti-malarial drug ...
OCT 13, 2019
Chemistry & Physics
OCT 13, 2019
Chemists Synthesized Effective Antidote For Uranium Poisoning
Uranium poisoning is unusual to the general population but does happen to miners, mineral mill and fabrication workers. Through inhaling and ingestion, ura...
OCT 13, 2019
Immunology
OCT 13, 2019
A New Way To Fight Severe Peanut Allergies
Dr. Sandra Lin explains how SLIT is currently being used to treat allergies other than peanuts.    Over 1 million U.S. children have an allergy t...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Does Modafinil Really Increase Brain Function?
Modafinil, often sold under the name “Provigil”, is a wakefulness-promoting drug used to treat excessive sleeping in conditions such as narcole...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Compound in Daffodils Can Help Fight Cancer
Preventing the growth of tumors presents a challenge for scientists in finding a cure to cancer. Now however, researchers from the University Libre de Brux...
Loading Comments...